The use of toceranib phosphate after surgical resection of haemangiosarcoma from the aortic arch in a German Shepherd dog

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16170%2F19%3A43877634" target="_blank" >RIV/62157124:16170/19:43877634 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

The use of toceranib phosphate after surgical resection of haemangiosarcoma from the aortic arch in a German Shepherd dog

Original language description

To report the post-operative outcome and survival of a dog after surgical resection of a haemangiosarcoma from the aortic arch using toceranib phosphate as an adjunctive therapy. Methods: Case report of a single patient treated with metronomic chemotherapy instead of conventional high-dose chemotherapy for adjuvant therapy of hemangiosarcoma of the aortic wall. Results: A 7-year-old male German Shepherd dog presented for investigation of lethargy. Pleural, peritoneal and pericardial effusion were identified, and echocardiography was indicative of a heart-based mass. The mass was surgically excised from the aortic arch and a subtotal pericardiectomy performed. Histology confirmed the mass was an incompletely excised haemangiosarcoma. The patient was started on epirubicin protocol (25mg/m2) but developed a severe septic neutropenia and thrombocytopenia. This recurred following the second treatment of epirubicin despite a dose reduction of 10%. Consequently, the patient was started on metronomic chemotherapy with toceranib phosphate (80mg orally Monday, Wednesday and Friday weekly). Eight months following the diagnosis the patient remains systemically well on metronomic chemotherapy with an excellent quality of life. Repeat staging has been negative for local and distant metastases but shows tissue thickening at the level of the aortic arch. Clinical Significance: Metronomic chemotherapy has been proposed for adjuvant therapy in dogs that do not tolerate conventional anthracycline based chemotherapy protocols. This is the first reported case of the use of a tyrosine kinase inhibitor as an adjuvant therapy for cardiac haemangiosarcoma. Conflict of interest and funding: The authors declared no potential conflicts of interest and no financial support with respect to the research, authorship, and/or publication of this abstract.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

40301 - Veterinary science

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů